Cleerly ISCHEMIA vs EchoNext

Cleerly ISCHEMIA offers comprehensive interactive web-based reports and 3D digital models of coronary arteries, providing a highly visual and detailed user experience. It also integrates with PowerScribe via API, suggesting a streamlined workflow for radiologists. EchoNext, while available through a clinical decision support platform, focuses on ECG analysis, which is a simpler input, but its output and reporting features are not as extensively detailed in the provided information as Cleerly's visual reports.

Cleerly ISCHEMIA provides non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, and detailed coronary plaque characterization, offering a comprehensive assessment of heart disease. It has been validated in multiple clinical trials, demonstrating higher diagnostic accuracy and prognostic utility compared to other non-invasive measures. EchoNext detects hidden structural heart disease from ECGs and has shown higher accuracy than cardiologists in identifying structural heart problems. However, Cleerly's detailed plaque analysis and FFR estimation offer a more in-depth understanding of coronary artery disease progression and risk.

EchoNext has transparent tiered pricing starting at $600/month, with discounts available, making its cost structure clear to potential users. Cleerly ISCHEMIA's pricing is 'contact for details' and 'varies by provider,' which offers less transparency upfront. While Cleerly's analysis may cost between $500 and $1,500 on top of the CTA, EchoNext's subscription model could be more predictable for ongoing use.

Both tools demonstrate strong enterprise readiness. Cleerly ISCHEMIA is HIPAA compliant, has a BAA, and is deployed via a web-based platform with data transfer options, indicating robust security and integration capabilities. EchoNext is also HIPAA compliant, has a BAA, and is available through the OpenEvidence clinical decision support platform, which serves a large physician base. Both are FDA-cleared, further supporting their readiness for clinical adoption in enterprise settings.

Both tools represent significant innovation in cardiology AI. Cleerly ISCHEMIA offers AI-enabled CCTA analysis for non-invasive FFR estimation and detailed plaque characterization, providing a novel approach to understanding coronary artery disease. EchoNext innovates by detecting hidden structural heart disease from standard ECGs, a widely available and inexpensive test, which can significantly broaden early detection efforts. The choice of winner depends on whether the innovation in advanced imaging analysis (Cleerly) or widespread, early screening (EchoNext) is prioritized.

Both companies indicate a commitment to supporting their products. Cleerly provides comprehensive reports and integration capabilities, suggesting good documentation for implementation and use. EchoNext's collaboration with OpenEvidence implies access to a broad support network for its users. However, specific details about the breadth and depth of their support and documentation (e.g., online knowledge bases, dedicated support teams, training programs) are not explicitly provided for either tool, leading to a tie.